Transient HBs antigenemia in patients on hemodialysis;Antigenemia transitoria de superficie de la hepatitis B en pacientes en hemodialisis

Revista Clinica Espanola

Volumn 199, Issue 4, 1999, Pages 198-201

  Santana Rodriguez O E ^b   Morillas Jarillo, C ^b   Esparza Martin N ^b   Toledo Gonzalez A ^b   Checa Andres M D ^b   Martin Sanchez A M ^a  

^a Centro de Ciencias de la Salud   (Spain)

^b NONE

Author keywords

Antigenemia; HBsAg; Hemodialysis; Hepatitis B vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ERROR; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; VACCINATION; VIRUS INFECTIVITY;

ADULT; AGED; ANTIGENS, SURFACE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 0032912398     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hautbiz M, Ehlerding G, Beigel A, Heuer V, Hemmerling AE, Thema HA. Clinical experience with a new recombinant hepatitis B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996; 45 (3):180-182.
2. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12 (6):1.204-1.211.
3. Zannolli R, Morgese G. Hepatitis B vaccine: current issues. Ann Pharmacother 1997; 31 (9):1.059-1.067.
4. Peces R, De la Torre M, Alcázar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997; 29 (2):239-245.
5. Mitwali A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73(3):417-420.
6. Vlassopoulos D, Arvanitis D, Lilis D, Hatjiyannakos D, Louizou K, Hadjiconstantinou V. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997; 19(3):455-460.
7. Santana OE, Francés A, Sierra A, Hernández J, Martín-Sánchez AM. Marcadores serológicos de hepatitis B: patrones atípicos detectados en el Hospital Insular de Gran Canaria. Rev Clín Esp 1995; 195:674-677.
8. Valliammai T, Echevarría JM, León P, Tusets C, Harrison TJ. Amplification and sequence analysis of the precore and core region of the HBV genome from sera of Spanish patients with HBV-2-like infections. J Med Virol 1995; 46:375-379.
9. Challapalli M, Slosar M, Vasa R, Cunningham DG. Brief surface antigenemia in newborn infants vaccinated with hepatitis B vaccine. Pediatr Infect Dis J 1993; 12:878-879.
10. Köksal N, Altinkaya N, Perk Y. Transient hepatitis B surface antigenemia after neonatal hepatitis B immunization. Acta Paediatr 1996; 85 (12): 1.501-1.502.
11. Kloster B, Kramer R, Eastlund T, Grossman B, Zarvan B. Hepatitis B surface antigenemia in blood donors following vaccination. Transfusion 1995; 35:475-477.
12. Kear TM, Wright LS. Transient hepatitis B antigenernia in hemodialysis following hepatitis B vaccination. Ann J 1996; 23 (3):331.
13. Janzen L, Minuk GY, Fast M, Bernstein KN. Vaccine-induced hepatitis B surface antigen positivity in adults hemodialysis patients: incidental and surve llance data. J Am Soc Nephrol 1996; 7 (8): 1.228-1.234.